India's Pharma PLI Scheme, halfway through, has doubled investment, boosting production and global market entry.

• The program targets high‑value drug manufacturing, diversifying products, and strengthening domestic capabilities for economic growth benefits.
• Investment commitment of ₹17,275 crore was surpassed, reaching ₹38,543 crore within three years of the program timeline.
• The goal includes integrating Indian pharma firms into global value chains, enhancing export potential, and promoting growth.